Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / ERBB2



This biomarker is also known as:
  • Tyrosine kinase-type cell surface receptor HER2,
  • Receptor tyrosine-protein kinase erbB-2,
  • CD340,
  • CD_antigen=CD340,
  • c-ErbB-2,
  • HER2,
  • Proto-oncogene Neu,
  • HER-2,
  • Metastatic lymph node gene 19 protein,
  • NGL,
  • Proto-oncogene c-ErbB-2,
  • p185erbB2,
  • TKR1,
  • NEU,
  • v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian),
  • MLN19,
  • HER-2/neu,
  • MLN 19,
  • v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog),

View in BioMuta


ERBB2, often known as HER-2/neu, a single-pass type I membrane protein, is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It is part of several cell surface receptor complexes. ERBB2 has no ligand binding domain of its own, and needs a coreceptor for ligand binding. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele Ile654/Ile655. There are several transcript variants resulting from alternative splicing events. Some isoforms have not been fully characterized yet.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


Performance Comment



Phase: Two
QA State: Under Review


Amplification and/or overexpression of the ERBB2 gene has been reported in numerous cancers, including breast and ovarian tumors. Studies have suggested that ERBB2 overexpression represented a major negative prognostic indicator for patients with several human cancers, including endometrial carcinomas

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.